Genelink Inc GNLKQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–0.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $265.02
- Volume/Avg
- 359,735 / 270,651
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- http://www.genelinkbio.com
Valuation
|
Metric
|
GNLKQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GNLKQ
|
|---|---|
Quick Ratio | 0.12 |
Current Ratio | 0.34 |
Interest Coverage | −8.02 |
Quick Ratio
No chart available
Profitability
|
Metric
|
GNLKQ
|
|---|---|
Return on Assets (Normalized) | −147.02% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
No chart available
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jvgbvtzch | Jzgbg | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pkjlkdq | Hvwfrdl | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jlfwckrp | Jmvblm | $97.3 Bil | |
MRNA
| Moderna Inc | Tcrrtjgv | Qmyvq | $41.3 Bil | |
ARGX
| argenx SE ADR | Gylbhbhj | Nbvqf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lbzmgmphb | Dprvf | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Shjfkmtw | Qgqvdbm | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zsssnhgx | Mmhhdb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jldfdrhn | Vcqgqs | $12.6 Bil | |
INCY
| Incyte Corp | Nggcmbl | Zxbfwk | $11.6 Bil |